An aerospace leader is surging after beating earnings estimates, a major telecom firm’s stock is down due to unexpected subscriber losses, and a hypertension-focused biotech is soaring 40% after its pacemaker-based therapy received FDA breakthrough status.
Here’s what’s moving the markets today.
Electric aviation isn’t just the future—it’s starting to take off now.
The race toward sustainable air travel is heating up, and this one company is well positioned against the competitors trading at much higher valuations.
They just secured $50 million in financing, strengthening their balance sheet and adding serious momentum to their transformation plan.
With revenue over $119 million in 2024, they’re not just competing; they’re a leader in the regional air travel space.
And trading for under $3 on the NYSE, its clear operational vision positions it to take advantage of a potential $75B+ growth industry.
*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
Earnings:
Tesla, Inc. [TSLA]: Afterhours
Intuitive Surgical, Inc. [ISRG]: Afterhours
Chubb Limited [CB]: Afterhours
Economic Reports:
Philadelphia Fed President Patrick Harker will speak at 9:30 am
Minneapolis Fed President Neel Kashkari will speak at 2:00 pm
Richmond Fed President Tom Barkin will speak at 2:30 pm
On Behalf of Azincourt Energy Corp
When Peter Thiel joins the board of a uranium enrichment startup and backs a $50 million raise, you pay attention.
Because this isn’t just Thiel.
It’s Gates with TerraPower. Bezos with General Fusion. Altman with Oklo. And now Thiel with General Matter.
The smartest minds of this generation are placing billion-dollar bets on one thing: Nuclear.
And it’s not hard to see why.
Global electricity demand is set to soar 50% by 2050.
AI. Data centers. EVs. Every megatrend needs power — and clean, baseload nuclear is the only source that scales.
Meanwhile, uranium production can’t keep up.
That’s why a tiny uranium explorer in the Athabasca Basin — home to the world’s highest-grade deposits — may soon be on every investor's radar.
Drill programs are planned. Momentum is building. And the market hasn’t caught up.
*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
GE Aerospace (NYSE: GE) shares are climbing 1% in premarket trading after the company reported better-than-expected earnings for the first quarter and reaffirmed its full-year outlook despite global tariff pressures.
The aerospace firm posted adjusted earnings per share of $1.49 on revenue of $9.94 billion, exceeding analyst expectations of $1.26 EPS and $9.77 billion in revenue.
The company also maintained its guidance for full-year adjusted EPS between $5.10 and $5.45.
CEO Larry Culp attributed the strong performance to disciplined cost control and a commercial services backlog exceeding $140 billion.
He emphasized the company’s proactive steps to cushion the impact of tariffs, including optimizing operations, adjusting pricing, and leveraging trade support programs.
The results mark a solid start to GE Aerospace’s second year as an independent company following its split from GE Vernova (NYSE: GEV).
Earlier this year, the firm announced plans to invest nearly $1 billion into its U.S. manufacturing footprint and supply chain—doubling its 2024 investment.
Despite recent concerns over tariff exposure that rattled all three former GE divisions, analyst sentiment remains positive.
Verizon Communications (NYSE: VZ) is reporting better-than-expected first-quarter results Tuesday morning, but its shares are down 3.3% in premarket trade due to an unexpected rise in customer churn.
The telecom giant posted adjusted earnings of $1.19 per share, beating analysts’ expectations of $1.15, according to a FactSet poll.
Total revenue rose 1.5% year-over-year to $33.5 billion, slightly ahead of the $33.3 billion estimate.
Wireless service revenue increased by 2.7% to $20.8 billion, and wireless equipment sales rose 0.7% to $5.4 billion.
Free cash flow grew to $3.6 billion, up from $2.7 billion in the same quarter last year.
Despite these positives, Verizon logged 289,000 net losses in postpaid phone subscribers—well above the 197,000 decline analysts had anticipated.
Inflation concerns, partly tied to new tariffs under President Donald Trump’s administration, may be driving customers toward more affordable plans, creating longer-term retention risks.
The company reaffirmed its full-year outlook, projecting flat to 3% growth in adjusted EPS for 2025.
However, it noted the forecast does not yet incorporate any potential tariff-related impacts on consumer behavior or costs.
Verizon’s stock has gained 7.4% year-to-date, outperforming the S&P 500 (INDEXSP: .INX), which is down 12% in 2025.
Its relatively stable domestic business and 6.3% dividend yield have helped insulate it from broader market volatility, especially as it becomes the first of the major U.S. wireless carriers to report earnings this season.
Looking for the next big EV opportunity?
The market is expanding rapidly, and one stock is standing out with its innovative approach and strong industry partnerships.
Find out more about this potential game-changer.
*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
RTX Corporation (NYSE: RTX) reported first-quarter results that outpaced analyst expectations, buoyed by strong demand for jet maintenance services.
The company also reaffirmed its 2025 guidance, despite softness in its defense division and a challenging global trade backdrop.
For the quarter ending March 31, RTX reported adjusted earnings per share of $1.47, topping the $1.35 consensus estimate compiled by LSEG.
Don’t miss: A hidden options system has worked 97% of the time for 8 years—find out the exact phrase now. (ad)
Total revenue reached $20.31 billion, beating forecasts of $19.79 billion.
The solid performance was driven largely by continued demand in commercial aviation services.
Collins Aerospace, RTX’s avionics and systems arm, recorded an 8% year-over-year revenue increase to $7.22 billion.
Pratt & Whitney, which supplies engines for Airbus’ A320neo, posted a 14% sales gain as airlines ramped up service requests for aging fleets.
However, Pratt continues to navigate challenges linked to inspections of its Geared Turbofan engines, which have grounded hundreds of aircraft due to potential defects.
Meanwhile, Raytheon, RTX’s defense arm, saw revenue fall 5%, reflecting the sale of its cybersecurity and intelligence business last year.
This is perhaps the reason why RTX shares are down nearly 4% in premarket.
Despite that, geopolitical tensions and a possible loosening of U.S. military export rules under President Donald Trump could offer future tailwinds for defense suppliers.
CEO Chris Calio optimistically highlighted the company’s strong backlog and operational readiness in a “very dynamic” environment.
RTX reiterated its full-year outlook, signaling confidence in navigating both commercial and political uncertainty.
Meiwu Technology has successfully regained compliance with Nasdaq’s minimum bid price requirement, lifting a cloud that had loomed over its stock and causing it to surge nearly 100% in premarket today.
The Shenzhen-based firm, which previously focused on food and SMS sales, is now pivoting into the functional skincare market through its subsidiary Chunshang Xiamen.
My Take: Meiwu’s regained compliance buys it time—but the success of its skincare pivot will determine long-term viability. Watch for revenue traction and consumer response in China’s crowded skincare space.
Calix is a broadband technology provider.
Despite year-over-year dips in earnings and revenue, the company surprised investors today with better-than-expected Q1 results and an upbeat Q2 outlook, fueling a 13% surge in premarket trading.
My Take: Calix’s solid Q2 guidance combined with aggressive buybacks could signal a turnaround quarter for the firm. If broadband infrastructure investment stays hot, CALX may have more upside ahead.
Orchestra BioMed is a biomedical innovation company pioneering advanced therapies through strategic collaborations.
The stock is growing 40% in premarket trading after the FDA granted Breakthrough Device Designation to its AVIM therapy—an implantable pacemaker-based system for treating uncontrolled hypertension in patients with high cardiovascular risk.
My Take: OBIO’s FDA breakthrough status is a major milestone that elevates its credibility and market potential. With Medtronic backing and a clear regulatory path, this could be a sleeper biotech stock with high long-term upside.
Electric aviation is no longer just a vision—it’s rapidly becoming reality. Major players are jumping in.
Toyota has invested $500 million to support electric air taxis.
United Airlines has already ordered hundreds of electric aircraft for future regional air travel.
And even the US Air Force is testing electric air taxis.
But one company is ahead of the pack.
This NYSE-listed stock just secured a $50 million financing, strengthening its balance sheet and adding fuel to its transformation plan.
With over $119 million in revenue in 2024, they’re not just joining the boom; they’re helping set the pace.
While others are gearing up, this company is already generating real results, flying passengers today on its network of regional flights across the U.S. using aircraft that could one day upgrade to electrified technology.
Trading for under $3, it’s well positioned in a potential growth industry that’s still in its early days.
Eli Lilly’s new obesity pill trial rattles Novo Nordisk investors with promising weight-loss data.
Modi and Vance highlight progress but challenges remain in U.S.-India trade talks.
Walgreens agrees to a $350M payout to end their years-long opioid litigation and avoid a trial.
Roche responds to trade pressures with a $50B five-year U.S. investment and an export shift.
W. R. Berkley sees strong growth in premiums and investments despite industry challenges.
Equity LifeStyle Properties expands guidance after topping Wall Street expectations.
Medpace beats profit forecasts, but a bookings slump sends shares plummeting.
AGNC surprises with better-than-expected adjusted earnings amid a profit slide.
Western Alliance posts improved Q1 results, but sales fall short of forecasts.
Revenue growth helps Wintrust top estimates in a mixed quarter.
A tax law change weighs on Zions’ results as shares slip in after-hours trading.
BOK Financial struggles to meet estimates as momentum from prior quarters fades.
Cadence Bank sees higher Q1 income as revenue growth remains modest.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Adam Garcia
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
*Standard message/carrier rates may apply.
Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.